杜比实验室 2026年季度报告

Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended December26, 2025 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period FromToCommission File Number: 001-32431 DOLBY LABORATORIES, INC. (Exact name of registrant as specified in its charter) 90-0199783(I.R.S. Employer Identification No.) Delaware(State or other jurisdiction of incorporation or organization) (415) 558-0200(Registrant’s telephone number, including area code) Indicate by check mark whether the registrant (1)has filed all reports required to be filed by Section13 or 15(d) of theSecurities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required tofile such reports), and (2)has been subject to such filing requirements for the past 90 days. Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to besubmitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for suchshorter period that the registrant was required to submit such files). Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, asmaller reporting company, or an emerging growth company.See definitions of "large accelerated filer," "accelerated filer,""smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act. Large Accelerated Filer☒Accelerated Filer☐Non-accelerated Filer☐Smaller Reporting Company☐Emerging Growth Company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complyingwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒ On January23, 2026, the registrant had 60,884,768 shares of ClassA common stock, par value $0.001 per share, and34,655,045 shares of Class B common stock, par value $0.001 per share, outstanding. DOLBY LABORATORIES, INC.FORM 10-QFor the Fiscal Quarter Ended December26, 2025TABLE OF CONTENTS PART I – FINANCIAL INFORMATION Item1.Unaudited Interim Condensed Consolidated Financial StatementsUnaudited Interim Condensed Consolidated Balance SheetsUnaudited Interim Condensed Consolidated Statements of OperationsUnaudited Interim Condensed Consolidated Statements of Comprehensive IncomeUnaudited Interim Condensed Consolidated Statements of Stockholders' EquityUnaudited Interim Condensed Consolidated Statements of Cash FlowsNotes to Unaudited Interim Condensed Consolidated Financial StatementsItem2.Management’s Discussion and Analysis of Financial Condition and Results of OperationsItem3.Quantitative and Qualitative Disclosures About Market RiskItem4.Controls and Procedures PART II – OTHER INFORMATION Item1.Legal ProceedingsItem1A.Risk FactorsItem2.Unregistered Sales of Equity Securities and Use of ProceedsItem 5.Other InformationItem6.ExhibitsSignature GLOSSARY OF TERMS PART I – FINANCIAL INFORMATION ITEM1. UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS DOLBY LABORATORIES, INC.INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS(in thousands, except share and per share amounts)(unaudited) DOLBY LABORATORIES, INC.INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(in thousands, except per share amounts) DOLBY LABORATORIES, INC.INTERIM CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME(in thousands)(unaudited) See accompanying notes to unaudited interim condensed consolidated financial statements DOLBY LABORATORIES, INC.INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(in thousands) DOLBY LABORATORIES, INC.NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 1. Basis of Presentation Unaudited Interim Condensed Consolidated Financial Statements We have prepared the accompanying unaudited interim condensed consolidated financial statements in accordance withU.S. GAAP, and with SEC rules and regulations, which allow for certain information and footnote disclosures that are normallyincluded in annual financial statements prepared in accordance with U.S. GAAP to be condensed or omitted. In our opinion,these unaudited interim condensed consolidated financial statements have been prepared on the same basis as the auditedconsolidated financial statements for the fiscal year ended September26, 2025 and include all adjustments necessary for fairpresentation. The accompanying unaudited interim condensed consolidated financial statements should be read in conjunctionwith our consolidated financial statements for the fiscal year ended September26, 2025, which are included in our AnnualReport on Form 10-K filed w